Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 26Prostatic Neoplasms, Castration-Resistant 4Prostatic Diseases 3Neoplasm Metastasis 3Metastatic Castration-resistant Prostate Cancer 3Adenocarcinoma 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Male Urogenital Diseases 2Genital Diseases, Male 2Urogenital Diseases 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Metastatic 1Non-metastatic Castration-resistant Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1High-Risk Localized Prostate Cancer 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Solid Tumor 1

Interventions

pembrolizumab 2darolutamide 2relatlimab 1olaparib 1gedatolisib 1enfortumab vedotin 1Surveys and Questionnaires 1Radiation Dose Hypofractionation 1Pluvicto 1Nivolumab 1Mitomycin 1Gemcitabine 1Fluorouracil 1Cisplatin 1CP protocol 1Blood Specimen Collection 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Male Urogenital Diseases × darolutamide × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07103018 2026-03-23

STRIKE-001

K36 Therapeutics, Inc.

Phase 1 Recruiting
144 enrolled
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡